Johnson & Johnson (NYSE:JNJ) Position Increased by Legacy Financial Advisors Inc.

Legacy Financial Advisors Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 4.2% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 13,573 shares of the company’s stock after acquiring an additional 544 shares during the period. Johnson & Johnson accounts for 0.5% of Legacy Financial Advisors Inc.’s portfolio, making the stock its 18th biggest holding. Legacy Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $2,406,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of JNJ. Family CFO Inc bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $26,000. Steward Financial Group LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth about $34,000. Joseph P. Lucia & Associates LLC acquired a new stake in Johnson & Johnson in the first quarter worth about $38,000. Advocacy Wealth Management Services LLC lifted its holdings in Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after purchasing an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth about $49,000. Institutional investors own 68.78% of the company’s stock.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on JNJ shares. UBS Group reduced their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Raymond James upped their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Citigroup reduced their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Finally, Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating for the company. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Price Performance

JNJ stock opened at $171.11 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.14 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The firm has a market capitalization of $449.88 billion, a PE ratio of 24.91, a P/E/G ratio of 3.32 and a beta of 0.59. The firm has a 50-day moving average of $175.21 and a two-hundred day moving average of $174.55.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. During the same period in the prior year, the firm earned $2.48 earnings per share. The business’s quarterly revenue was up 3.0% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.64%. Johnson & Johnson’s dividend payout ratio is 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.